Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

• Status: Not yet recruiting
• Trial end date: 2028-04-30
• Target enrollment: 0
• Participant gender: All

Summary

This study is a study of ocrelizumab (OCR) treatment-discontinuation in patients with early Relapsing Remitting Multiple Sclerosis (RRMS). All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at month 6 and month 12. At month 12, participants will be randomized (1:1:1) to one of three Arms: Arm 1: placebo infusions every 6 months; Arm 2: OCR infusions at months 18 and 24 and then after month 24 switch to placebo infusions every 6 months; Arm 3: OCR infusions every 6 months. The treatment period will be for a total of 48 months.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Collaborator: Autoimmunity Centers of Excellence (ACE)
• Treatments: Ocrelizumab

Criteria

Inclusion Criteria:

1. Have at least one clinical episode that satisfies McDonald 2017 criteria for early Multiple sclerosis (MS) for up to 2 years post-event with a dissemination in time that can be met clinically, by Magnetic Resonance Imaging (MRI), or based on oligoclonal band (OCB) positivity

2. Have a length of disease duration, from first symptom, of ≤ 2 years

3. For women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use effective methods of contraception during the treatment period and for at least 6 months after the last dose of study drug:

1. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus)

2. Examples of contraceptive methods include bilateral tubal ligation, male sterilization, established hormonal contraceptives that inhibit ovulation, hormone- releasing intrauterine devices, and copper intrauterine devices

3. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post ovulation methods) and withdrawal are not acceptable methods of contraception

4. Barrier methods must always be supplemented with the use of a spermicide

4. Immunization with one of the Food and Drug Administration (FDA) authorized or licensed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 vaccines)

Exclusion Criteria:

1. Inability or unwillingness of a participant to give written informed consent or comply with study protocol

2. History of Primary Progressive Multiple Sclerosis (PPMS), Progressive Relapsing Multiple Sclerosis (PRMS), or Secondary Progressive Multiple Sclerosis (SPMS)

3. Any metallic material or electronic device in the body, or condition that precludes the participant from undergoing Magnetic resonance imaging (MRI)

4. Known presence or history of other neurological disorders, including but not limited to the following:

1. Ischemic cerebrovascular disorders, including but not limited to transient ischemic attack, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism, or cerebral hemorrhage

2. Central Nervous System (CNS) or spinal cord tumor, metabolic or infectious cause of myelopathy, genetically inherited progressive CNS disorder, CNS sarcoidosis, or systemic autoimmune disorders potentially causing progressive neurologic disease or affecting ability to perform the study assessments

5. Pregnancy or lactation

a. Female participants of childbearing potential must have a negative urine pregnancy test at screening

6. Any concomitant disease that may require chronic systemic treatment with corticosteroids or immunosuppressants during the course of the study

7. Lack of peripheral venous access

8. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies

9. Significant, inadequately controlled (e.g. diagnostic evaluations indicated or change in medications warranted) disease, such as cardiovascular (including cardiac arrhythmia), pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine, and gastrointestinal or any other significant disease that in the opinion of the investigator may preclude participant from participating in the study

10. Functional status of NY Heart Association (NYHA) Class III or higher for heart failure at the screening visit

11. Known active bacterial, viral, fungal, mycobacterial infection or other infection (including tuberculosis [TB] or atypical mycobacterial disease but excluding limited superficial fungal or viral infections of the skin or nails) or any severe episode of infection requiring hospitalization or treatment with Intravenous (IV) antibiotics within 4 weeks prior to baseline visit or oral antibiotics within 2 weeks prior to baseline visit

12. Active or chronic infection with Human Immunodeficiency Virus (HIV), syphilis or TB (see laboratory tests below)

13. Evidence of past or current hepatitis B or hepatitis C infection, including treated hepatitis B or hepatitis C. Hepatitis B surface antibody following hepatitis B immunization is not considered to be evidence of past infection

14. Known active malignancy or active monitoring for recurrence of malignancy, including solid tumors and hematological malignancies, except basal cell, in situ squamous cell carcinoma of the skin, and in situ carcinoma of the cervix for the uterus that have been excised with clear margins

15. Substance use disorder, including the recurrent use of alcohol and /or drugs within the past year associated with clinically significant impairment associated with failure to meet major responsibilities at work, school, or home

16. Receipt of a live vaccine within 6 weeks prior to baseline; in rare cases when participant requires vaccination with a live vaccine, the screening period may need to be extended but cannot exceed 8 weeks

17. Contraindications to or intolerance of oral or IV corticosteroids, including Intravenous (IV) methylprednisolone administered according to the country label, including:

1. Psychosis not yet controlled by a treatment

2. Hypersensitivity to any of the constituents preceding

18. Treatment with any Multiple sclerosis (MS) disease-modifying treatments (DMTs) including but not limited to: glatiramer acetate preparations, beta-interferon preparations, fingolimod and related agents, fumarates, cladribine, natalizumab, anti-CD20 molecules, alemtuzumab, and chemotherapeutic agents

19. Current or prior treatment with any investigational agent or treatment with any experimental procedure for MS (e.g. treatment for chronic cerebrospinal venous insufficiency)

20. Systemic corticosteroid therapy within 4 weeks prior to screening

21. Laboratory test results as follows:

a. Positive infection screening tests for:

i. Hepatitis C (HCV) antibody, if positive screen for HCV RNA Polymerase Chain Reaction (PCR)

ii. Rapid plasma reagin (RPR)

iii. HIV

iv. At or within twelve months of screening:

• Positive QuantiFERON(R)-TB Gold test or positive purified protein derivative tuberculin skin test (PPD) (>5mm induration, regardless of Bacille Calmette Guerin [BCG] vaccine administration) unless completion of treatment has been documented for active TB

• An indeterminate QuantiFERON(R)-TB Gold test unless followed by a subsequent negative PPD or negative QuantiFERON(R)-TB Gold test as well as a consultation with and clearance by local infectious disease (ID) department

b. CD4 count<250 cells/mcL

c. Levels of serum IgG<565 mg/dL

d. Levels of serum IgM<40 mg/dL

e. End stage renal disease estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m^2 using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation

f. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)>= 2.0 x the upper limit of normal (ULN)

g. Platelet count < 100,000 plt/mcL (< 100 x 10^9/L)

h. Hemoglobin < 10 g/dL

i. Total neutrophil count < 1.5 x 10^3/mL

22. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study